Genmab — Marts 2023
-
-
Immatics presentation shows Genmab collaboration still preclinical https://investors.immatics.com/static-files/0df36fcf-308b-4e29-afe7-c83c562abab6
-
Morn, Biotech industrien lader til at have en PE værdi omkring 35. De fleste firmaer indenfor biotech vlkster under 10% om året og kære med underskud og vil derfor mene at et firma som Genmab som år efter år vækster med 35% bør handles til PE i 35-50 niveau. https://www.saxotrader.com/sim/instant-demo/InstantDemo-EN-GL/news/202303220932SAXOBANKPLATEQUT31456778?cmpid=copy_link_platform_sharing
-
-
Godmorgen

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind